HomeBIOTECHNOLOGY
BIOTECHNOLOGY
Medical Device News Magazine reports breaking biotechnology news in addition to medical device news.
CERo Therapeutics Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
CERo Therapeutics is continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA
New US Headquarters Opened By Mass Photometry Pioneers Refeyn
Serving as Refeyn’s US Customer Interaction Center, alongside offices, meeting and training rooms, the leading-edge laboratory space in the new HQ now enables customers across North America to visit to run samples and test applications. Refeyn is working to achieve sustainability certification for this laboratory space, which includes a BSL-2 lab, service center, R&D center and applications lab. The new site also facilitates instrument maintenance, customer training sessions, and workshops that all serve to ensure excellence in support for Refeyn’s customers across North America and beyond.
Tianlong Promotes Environmental Sustainability and Hygiene Monitoring with its Biolum Portable ATP Hygiene Monitoring System Series
Tianlong's Biolum Portable ATP Hygiene Monitoring System, a powerful tool for implementing and overseeing hygiene monitoring programs, has achieved outstanding performance, earning certification from the prestigious AOAC Research Institute's Performance Tested Methods (PTM) Program
Alchemab advances a novel antibody with potential in Parkinson’s disease with support from The Michael J. Fox Foundation
The grant was awarded through MJFF's Parkinson's Disease Therapeutics Pipeline Program. The program seeks to advance testing of promising therapeutic developments that address unmet medical needs in people with PD. The program is designed to fund therapeutic development with a clear focus to prevent, stop, or delay disease progression, or to reduce the challenges of daily symptoms.
MilliporeSigma Announces Completion of Schnelldorf Distribution Center Expansion
Expands facility by 25,000 square meters, nearly doubling size.
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
"We are thrilled with the DEA's decision, which underscores the potential of MIRA-55 as a groundbreaking therapeutic candidate," said Erez Aminov, Chairman & CEO of MIRA Pharmaceuticals. "This ruling allows us to focus on MIRA-55's unique cognitive and anxiety benefits. With access to $90B traditional neurological and $30B cannabis markets, MIRA-55 represents a significant value proposition for our company. We remain committed to advancing it through the development pipeline for treating these diseases from which so many currently suffer."
Abu Dhabi Issues First BioTech Inventor-Class Golden Visa to Catalyze “Made-In-Abu-Dhabi IP” to Rockefeller University Inventor Dr Kambiz Shekdar, PhD
Dr Kambiz Shekdar said: "I gratefully take this opportunity as my solemn commitment to help build up the BioTech sector in Abu Dhabi with the same home-grown can-do-and-have-done record of accomplishment demonstrated by Emirati leadership, its people, and nation, and to do so collegially with the best of the best of the world's human capital across frontier technologies who, like myself, are drawn to the UAE with the thirst to pioneer and build better like only possible in the red-hot entrepreneurial climate of the UAE."
Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups
"We celebrate the growing base of research and technological advances within the region's health and life sciences sector," said Chandra Briggman, President and CEO of Activation Capital.
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models